Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Gynecologic 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Refractory/Relapse Neuroblastoma 1Papillomavirus Infections 1Osteoporosis 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Infertility 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Hodgkin Disease 1High Grade Cervical Intraepithelial Neoplasia 1Esophageal Neoplasms 1Burkitt Lymphoma 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Biological Products × Clear all
NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
127 enrolled
BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT00014131 2023-10-04

Vaccine Therapy in Treating Patients With Kidney Cancer

Lisata Therapeutics, Inc.

Phase 1 Terminated
9 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡